Surrozen, Inc. Share Price
NASDAQ: SRZN | Micro CapSurrozen, Inc. Stock Performance
Open $23.20 | Prev. Close $23.98 | Circuit Range N/A |
Day Range $22.50 - $23.20 | Year Range $11.05 - $34.27 | Volume 25,530 |
Average Traded $22.86 |
Surrozen, Inc. Share Price Today
As of 31 August 2026, Surrozen, Inc.'s share price is $22.42. The stock opened at $23.20, compared to its previous close of $23.98. During today's trading session, Surrozen, Inc.'s share price traded between $22.50 and $23.20, with an average price of $22.85. Over the past 52 weeks, the stock has recorded a high of $34.27 and a low of $11.05. In terms of performance, Surrozen, Inc.'s share price has declined by 19.24% over the last six months and is up 85.29% on a year-on-year basis.
Surrozen, Inc. Share Price Chart
Surrozen, Inc. Stock Fundamentals & Key Indicators
Market Cap $167656.76 | PE Ratio (TTM) -0.69 | Dividend Yield N/A |
EPS (TTM) $-32.37 | Revenue (TTM) $3.48M | Return On Equity (TTM) 128.90% |
Profit Margin -6960.77% | Debt to Equity -0.05 | Quarterly Earnings Growth YoY -4896.03% |
Surrozen, Inc. Quarterly Profit & Loss
All figures in USD
Surrozen, Inc. Annual Profit & Loss
All figures in USD
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Surrozen, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $21.48 | $24.04 | +7.47% |
Jul 2026 | $24.97 | $22.37 | -13.70% |
Jun 2026 | $24.95 | $25.92 | -0.73% |
May 2026 | $34.02 | $26.11 | -21.43% |
Apr 2026 | $29.25 | $33.23 | +14.07% |
Mar 2026 | $28.00 | $29.13 | +4.94% |
Feb 2026 | $21.37 | $27.76 | +28.76% |
Jan 2026 | $23.01 | $21.56 | -3.71% |
Dec 2025 | $16.10 | $22.39 | +35.08% |
Nov 2025 | $12.19 | $16.57 | +18.39% |
Oct 2025 | $13.72 | $14.00 | +16.86% |
Sep 2025 | $12.55 | $11.98 | -0.99% |
SRZN Share Price FAQs
What is Surrozen, Inc. share price today?
What is the 52 week high and 52 week low of Surrozen, Inc. stock?
What is SRZN's market capitalisation today?
What is SRZN's net income for the last quarter?
What is the 5 year returns of SRZN?
What is the high & low stock price of SRZN today?
Can I buy SRZN shares in India?